Peregrine Capital Management LLC Increases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Peregrine Capital Management LLC grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,804 shares of the biotechnology company's stock after purchasing an additional 11,965 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.06% of Sarepta Therapeutics worth $6,542,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SRPT. Atria Wealth Solutions Inc. grew its position in shares of Sarepta Therapeutics by 10.5% in the 4th quarter. Atria Wealth Solutions Inc. now owns 11,692 shares of the biotechnology company's stock worth $1,422,000 after buying an additional 1,108 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares during the period. Principal Financial Group Inc. lifted its stake in Sarepta Therapeutics by 5.6% in the fourth quarter. Principal Financial Group Inc. now owns 282,084 shares of the biotechnology company's stock worth $34,299,000 after acquiring an additional 15,047 shares during the period. State of New Jersey Common Pension Fund D lifted its stake in Sarepta Therapeutics by 1.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 33,033 shares of the biotechnology company's stock worth $4,016,000 after acquiring an additional 335 shares during the period. Finally, Manchester Capital Management LLC lifted its stake in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 110 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $2.13 during mid-day trading on Friday, reaching $106.28. The company's stock had a trading volume of 709,268 shares, compared to its average volume of 811,414. Sarepta Therapeutics, Inc. has a 12-month low of $101.15 and a 12-month high of $173.25. The firm's fifty day moving average price is $117.88 and its two-hundred day moving average price is $123.85. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $10.15 billion, a P/E ratio of 85.02 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SRPT. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. HC Wainwright reiterated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their target price for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Finally, StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $176.77.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.